Targeting, Attacking, and Eradicating Cancers®
Chief Executive Officer
Dr. Moon has served as Chief Executive Officer since February 2014. Dr. Moon graduated with honors from the School of Dentistry of Seoul National University in Korea and from Moscow Medical School in Russia where he concentrated in Head and Neck Surgery. He was appointed as a member of the Korea-Russia Association and also works as a consultant of the Academy of Foreign Affairs and National Security.
Chief Financial Officer,
Chief Business Officer
Mr. Song has served as the Executive Director and the Head of Management Planning and Management Support since January 2017, where he oversees general corporate management and planning. Prior to joining SillaJen, Mr. Song served as a director at KEB Hana Bank, managing corporate banking for over 20 years. Mr. Song graduated from Yonsei University with a degree in political science & international relations, and received his masters in public administration from Yonsei University graduate school.
Dr. Choi has served as a Director in R&D Strategy since August 2016, where she oversees various R&D projects and planning. Prior to joining SillaJen, she had served as a Bio-Industrial Engineering professor at Konkuk University in Korea and also a senior research associate at Salk Institute for Biological Studies in USA. Dr. Choi graduated from Sogang University with B.S. Biology in Korea and achieved Ph.D. Virology from Purdue University in USA.
Chief Medical Officer
Dr. Kwon has served as Chief Medical Officer at SillaJen since 2018, where he oversees global clinical development for SillaJen including design and oversight of clinical trials of gene and immunotherapy agents for hepatocellular carcinoma, renal cell carcinoma, colorectal cancer and various other solid tumors. Prior to joining SillaJen, he had served as a head of medical affairs at Celltrion Healthare and Genexine. Dr. Kwon achieved Ph.D. from Dong-A University in Korea.
Chief Operating Officer
Dr. Roth has served as Chief Operating Officer and Senior Vice President of Technical Operations at SillaJen Biotherapeutics, Inc. since 2014, where he is responsible for managing U.S. operations and heading all technical functions for the development of oncolytic viruses. Prior to SillaJen, he worked as Vice President of Technical Operations at Jennerex, with responsibilities in process development, analytical development and manufacturing of oncolytic viruses. Dr. Roth was Director of Technical Affairs at Dynavax and in 2008 established an international consulting company specializing in bioprocess technology. He also held positions of increasing responsibility at Berlex Laboratories. Altogether Dr. Roth has over 30 years of experience in the pharmaceutical industry. Dr. Roth holds a Ph.D. in Chemical Engineering from Technical University Berlin, Germany.
Senior Vice President of Regulatory Affairs and Quality Assurance
Dr. Fritsch has served as Senior Vice President of Regulatory Affairs and Quality Assurance at SillaJen Biotherapeutics, Inc. since April 2014 where she is responsible for managing regulatory and quality compliance. Dr. Fritsch has led Sillajen’s global regulatory strategy and worldwide agency negotiations for the company’s lead Phase 3 product (Pexa-Vec) and other projects at various stages of development. Prior to her position at SillaJen, she served as Vice President of Regulatory Affairs and Quality Assurance at Jennerex. She led the regulatory function at Onyx Pharmaceuticals, Anthera Pharmaceuticals and Peninsula Pharmaceuticals and had positions of increasing responsibility at Genentech. She has over 25 years of experience in managing regulatory affairs, compliance and quality. Dr. Fritsch received her Doctor of Pharmacy from Creighton University.